Yamamoto Hiroki, Shirasawa Masayuki, Naoki Katsuhiko
Department of Respiratory Medicine, Kitasato University, 1-15-1 Kitasato, Minami-Ku, Sagamihara, Kanagawa, 252-0373, Japan.
Int J Clin Oncol. 2025 Feb;30(2):199-209. doi: 10.1007/s10147-025-02695-4. Epub 2025 Jan 16.
In Japan, high-quality cancer statistics are collected through cancer registries. However, these data are rarely summarized or reported in research articles. We compiled statistical data on lung cancer in Japan including the COVID-19 pandemic. In 2019, the number of cases of lung cancer in Japan was 126,548. The age-adjusted incidence rate of lung cancer increased from 23.2/100,000 to 42.4/100,000 in males and from 7.2/100,000 to 18.3/100,000 in females between 1975 and 2019. The age-adjusted mortality rate of lung cancer in Japan increased since 2000, after which it decreased. This trend was similar in both males and females. We also investigated statistics on lung cancer worldwide (Australia, Sweden, England, and the United States [USA]). The age-adjusted incidence rate of lung cancer in the data standardized to the world population for males has increased only in Japan; for females, it has decreased only in the USA. Global age-adjusted lung cancer mortality rates have been declining in all countries. In addition, the COVID-19 pandemic has not affected the age-adjusted mortality rate of lung cancer. On the other hand, the number of individuals undergoing lung cancer screening in Japan decreased from 7.92 million in 2019 to 6.59 million in 2020. The COVID-19 pandemic may have affected individuals undergoing lung cancer screening, and its impact on lung cancer needs to be continuously monitored in the future.
在日本，高质量的癌症统计数据是通过癌症登记处收集的。然而，这些数据在研究文章中很少被总结或报道。我们汇编了包括新冠疫情期间在内的日本肺癌统计数据。2019年，日本肺癌病例数为126,548例。1975年至2019年间，日本男性肺癌年龄标准化发病率从23.2/10万增至42.4/10万，女性从7.2/10万增至18.3/10万。日本肺癌年龄标准化死亡率自2000年起上升，之后下降。男性和女性的这一趋势相似。我们还调查了全球（澳大利亚、瑞典、英国和美国）的肺癌统计数据。按世界人口标准化的数据中，男性肺癌年龄标准化发病率仅在日本上升；女性则仅在美国下降。全球肺癌年龄标准化死亡率在所有国家都呈下降趋势。此外，新冠疫情并未影响肺癌年龄标准化死亡率。另一方面，日本接受肺癌筛查的人数从2019年的792万降至2020年的659万。新冠疫情可能影响了接受肺癌筛查的人群，其对肺癌的影响未来需要持续监测。
